UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical impact of the CONUT score in patients with multiple myeloma

Annals of hematology, 2020, Vol.99 (1), p.113-119

2020

Volltextzugriff (PDF)

Long non-coding RNA MALAT1 facilitates the tumorigenesis, invasion and glycolysis of multiple myeloma via miR-1271-5p/SOX13 axis

Journal of cancer research and clinical oncology, 2020-02, Vol.146 (2), p.367-379

2020

Volltextzugriff (PDF)

Extramedullary Disease in Multiple Myeloma

Current hematologic malignancy reports, 2020-04, Vol.15 (2), p.62-71

2020

Volltextzugriff (PDF)

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

Cancer Immunology, Immunotherapy, 2013-12, Vol.62 (12), p.1841-1849

2013

Volltextzugriff (PDF)

The proteasome and proteasome inhibitors in multiple myeloma

Cancer and metastasis reviews, 2017-12, Vol.36 (4), p.561-584

2017

Volltextzugriff (PDF)

R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study

Annals of hematology, 2024-09, Vol.103 (9), p.3677-3690

2024

Volltextzugriff (PDF)

Challenges in the treatment of soft-tissue plasmacytoma: a retrospective analysis of 120 patients with extramedullary multiple myeloma

Journal of cancer research and clinical oncology, 2024-10, Vol.150 (10), p.482, Article 482

2024

Volltextzugriff (PDF)

Antibody-Based Treatment Approaches in Multiple Myeloma

Current hematologic malignancy reports, 2021-04, Vol.16 (2), p.183-191

2021

Volltextzugriff (PDF)

Molecular pathogenesis of multiple myeloma: basic and clinical updates

International journal of hematology, 2013-03, Vol.97 (3), p.313-323

2013

Volltextzugriff (PDF)

Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients

Annals of hematology, 2018-08, Vol.97 (8), p.1453-1462

2018

Volltextzugriff (PDF)

Navigating the treatment landscape in multiple myeloma: which combinations to use and when?

Annals of hematology, 2019-01, Vol.98 (1), p.1-18

2019

Volltextzugriff (PDF)

Lys-63-specific deubiquitinase BRCC36 enhances the sensitivity of multiple myeloma cells to lenalidomide by inhibiting lysosomal degradation of cereblon

Cellular and molecular life sciences : CMLS, 2024-12, Vol.81 (1), p.349, Article 349

2024

Volltextzugriff (PDF)

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

Cancer Immunology, Immunotherapy, 2015-01, Vol.64 (1), p.61-73

2015

Volltextzugriff (PDF)

Supportive Care in Multiple Myeloma

Current hematologic malignancy reports, 2020-04, Vol.15 (2), p.56-61

2020

Volltextzugriff (PDF)

Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma

Cellular and molecular life sciences : CMLS, 2021-04, Vol.78 (8), p.3883-3906

2021

Volltextzugriff (PDF)

Recent trends in incidence, survival and treatment of multiple myeloma in Finland – a nationwide cohort study

Annals of hematology, 2024-04, Vol.103 (4), p.1273-1284

2024

Volltextzugriff (PDF)

Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis

Annals of hematology, 2019-05, Vol.98 (5), p.1185-1195

2019

Volltextzugriff (PDF)

N6-methyladenosine-induced miR-182-5p promotes multiple myeloma tumorigenesis by regulating CAMK2N1

Molecular and cellular biochemistry, 2024-11, Vol.479 (11), p.3077-3089

2024

Volltextzugriff (PDF)

Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis

Annals of hematology, 2021-03, Vol.100 (3), p.725-734

2021

Volltextzugriff (PDF)

Autoimmune retinopathy in a patient with smoldering multiple myeloma: a case report

Documenta ophthalmologica, 2024-06, Vol.148 (3), p.167-171

2024

Volltextzugriff (PDF)

Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects

Current hematologic malignancy reports, 2020-04, Vol.15 (2), p.45-55

2020

Volltextzugriff (PDF)

Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma

Cancer chemotherapy and pharmacology, 2022-01, Vol.89 (1), p.129-140

2022

Volltextzugriff (PDF)

Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study

Supportive care in cancer, 2014-02, Vol.22 (2), p.417-426

2014

Volltextzugriff (PDF)

The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma—a single-centre, qualitative service evaluation study

Supportive care in cancer, 2024-07, Vol.32 (7), p.479, Article 479

2024

Volltextzugriff (PDF)

1 – 25 von 3.586

Suche als RSS-Feed

Aktive Filter

KollektionOxford Journals

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.387)
Mit Volltextzugriff
(3.433)

Publikationsform

Artikel
(3.585)
Tagungsberichte
(1)

Sprache

Englisch
(3.353)
Deutsch
(209)
Italienisch
(18)
Französisch
(13)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(23)
... seit 30 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Clinical impact of the CONUT score in patients with multiple myeloma

Population-based screening cohort study reveals no association between monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), multiple myeloma (MM), and alopecia

Long non-coding RNA MALAT1 facilitates the tumorigenesis, invasion and glycolysis of multiple myeloma via miR-1271-5p/SOX13 axis

Extramedullary Disease in Multiple Myeloma

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

The proteasome and proteasome inhibitors in multiple myeloma

R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study

Challenges in the treatment of soft-tissue plasmacytoma: a retrospective analysis of 120 patients with extramedullary multiple myeloma

Antibody-Based Treatment Approaches in Multiple Myeloma

Molecular pathogenesis of multiple myeloma: basic and clinical updates

Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients

Navigating the treatment landscape in multiple myeloma: which combinations to use and when?

Lys-63-specific deubiquitinase BRCC36 enhances the sensitivity of multiple myeloma cells to lenalidomide by inhibiting lysosomal degradation of cereblon

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

Supportive Care in Multiple Myeloma

Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma

Recent trends in incidence, survival and treatment of multiple myeloma in Finland – a nationwide cohort study

Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis

N6-methyladenosine-induced miR-182-5p promotes multiple myeloma tumorigenesis by regulating CAMK2N1

Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis

Autoimmune retinopathy in a patient with smoldering multiple myeloma: a case report

Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects

Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma

Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study

The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma—a single-centre, qualitative service evaluation study

Aktive Filter

Suchergebnisse filtern